Biora Therapeutics, Inc. Common Stock
BIOR
BIOR was delisted on the 10th of December, 2024.
42 hedge funds and large institutions have $8.72M invested in Biora Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 9 closing their positions.
277% more call options, than puts
Call options by funds: $226K | Put options by funds: $60K
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 44 → 42 (-2)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
64% less capital invested
Capital invested by funds: $24.1M → $8.72M (-$15.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Athyrium Capital Management
New York
|
+$3.65M |
| 2 |
AC
Armistice Capital
New York
|
+$2.44M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$373K |
| 4 |
Millennium Management
New York
|
+$270K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
-$3.17M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$76.8K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$55.1K |
| 4 |
Wolverine Trading
Chicago,
Illinois
|
-$36K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$22K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
51
Virtu Financial
New York
| – | -$5K | -41 | Closed |
|
52
CIBC Private Wealth Group
Atlanta,
Georgia
| – | -$5K | -40 | Closed |
|
53
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$73 | -1 | Closed |
|
|
NA
54
NewEdge Advisors
New Orleans,
Louisiana
| – | +$146 | +2 | New |
|
BIOR Hedge Fund Activity: Q4 2022 in Review
42 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q4 2022, worth a combined $8.72M — down 64% from $24.1M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of BIOR and 7 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 10 added.
The largest buyer was Athyrium Capital Management, adding an estimated $3.65M. The largest seller was Neuberger Berman Group, exiting entirely with an estimated $3.17M sold.
- 42 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q4 2022, down from 44 in Q3 2022.
- Funds reported $8.72M of Biora Therapeutics, Inc. Common Stock stock for Q4 2022, down 64% quarter-over-quarter.
- 7 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q4 2022 and 9 closed out, a net change of -2 holders.
- The largest Biora Therapeutics, Inc. Common Stock buyer in Q4 2022 was Athyrium Capital Management, an estimated $3.65M added.
- The largest Biora Therapeutics, Inc. Common Stock seller in Q4 2022 was Neuberger Berman Group, an estimated $3.17M sold.
Based on aggregated 13F filings for Q4 2022.